BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis

(2012) Matthew F. Kalady et al.   DISEASES OF THE COLON & RECTUM

Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer

(2012) Vlad Popovici et al.   JOURNAL OF CLINICAL ONCOLOGY

Trees, Forests, and Other Implications of aBRAFMutant Gene Signature in Patients WithBRAFWild-Type Disease

(2012) Jason E. Faris et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF Mutation Analysis of Fine-Needle Aspiration Biopsies of Papillary Thyroid Carcinoma: Impact on Diagnosis and Prognosis

(2011) Agnes Colanta et al.   ACTA CYTOLOGICA

Poorer Prognosis and Higher Prevalence of BRAF V600E Mutation in Synchronous Bilateral Papillary Thyroid Carcinoma

(2011) Weibin Wang et al.   ANNALS OF SURGICAL ONCOLOGY

Reclassification of serous ovarian carcinoma by a 2-tier system

(2011) Diane C. Bodurka et al.   CANCER

Low-grade serous carcinomas of the ovary contain very few point mutations

(2011) Siân Jones et al.   JOURNAL OF PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

(2010) Kwong-Kwok Wong et al.   AMERICAN JOURNAL OF PATHOLOGY

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

(2010) M. Janakiraman et al.   CANCER RESEARCH

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ovarian Low-grade and High-grade Serous Carcinoma

(2009) Russell Vang et al.   ADVANCES IN ANATOMIC PATHOLOGY

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

(2009) David M. Gershenson et al.   GYNECOLOGIC ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data

(2008) Russell Vang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

(2008) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY